Xconomy | Boston - Business + Technology in the Exponential Economy

Related Posts

Biotech, people, Drugs

Dyax Names Christensen New CEO; Blair Retiring

Luke Timmerman 10/20/08

Dyax, the Cambridge, MA-based drug developer, said today that Gustav Christensen will replace co-founder Henry Blair as president and CEO on Jan. 1. Christensen joined the company as chief business officer in April 2007. Blair, who co-founded the company in 1989, plans to retire as CEO but remain chairman of the board at Dyax.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share:   Retweet Facebook Email

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    
Xconomy network map Seattle Boston San Diego
national life-sciences startups

Most Popular Stories

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.